Vijaypd Ceutical Limited Revenue Rises 43.5% to ₹73.67 Crore
Key highlights
- Standalone H1 FY27 revenue rose 43.5% year on year to ₹73.67 crore.
- Standalone H1 FY27 net profit was ₹2.37 crore, down 1.9% from ₹2.42 crore.
- Finance charges increased to ₹1.33 crore from ₹1.06 crore in H1 FY26.
- Vijaypd Ceutical Limited deployed ₹10.83 crore of IPO proceeds on capex and ₹5.10 crore on debt repayment.
powered by IRIS

Vijaypd Ceutical Limited reported standalone revenue from operations of ₹73.67 crore for the half year ended September 30, 2026, up 43.5% year on year, while net profit declined 1.9% to ₹2.37 crore. The results show a sharp increase in sales but limited conversion of that growth into profit amid higher purchase costs and finance charges.
Know Vijaypd Ceutical inside out
Results, valuation, peers and who's buying, in one view.
What did Vijaypd Ceutical report for H1 FY27?
Vijaypd Ceutical reported standalone revenue from operations of ₹73.67 crore for H1 FY27, compared with ₹51.33 crore in H1 FY26. The half-year figures were approved by the board on November 14, 2026, for the period ended September 30, 2026.
Net profit for the six-month period was ₹2.37 crore, compared with ₹2.42 crore a year earlier. Basic earnings per share stood at ₹1.21, against ₹1.72 in H1 FY26. The lower EPS also reflects the company’s expanded equity base of ₹19.53 crore.
The filing did not include an earnings-call transcript or management guidance for the quarter. As a result, the reported figures provide the available basis for assessing the company’s operating and financial performance, without additional commentary on targets, demand conditions or future profitability.
Why did profit not match the revenue growth?
Vijaypd Ceutical’s profit did not rise alongside revenue because higher purchase costs and finance charges affected the result. Finance charges increased to ₹1.33 crore in H1 FY27 from ₹1.06 crore in the corresponding period of the previous year.
The company reported a standalone operating margin, measured in the available results summary as profit before tax divided by total income, of about 4.4% for the period ended September 30, 2026. This points to a relatively narrow profit cushion despite the increase in sales.
The reported standalone profit after tax of ₹2.37 crore was slightly below the prior-year figure. Therefore, the H1 outcome indicates that sales expansion did not fully offset the higher costs recorded during the period. The filing does not provide management guidance on whether these cost factors are temporary or likely to continue.
How do the consolidated H1 FY27 numbers compare?
Vijaypd Ceutical reported consolidated revenue from operations of ₹105.21 crore and consolidated net profit of ₹3.36 crore for H1 FY27. These figures include the financial performance of the group and are higher than the standalone numbers reported by the parent company.
The consolidated results summary showed total income of ₹105.7 crore, including other income of ₹0.5 crore. Consolidated profit before tax was ₹4.6 crore, while the reported operating margin was 4.4%. Consolidated revenue was stated to be 105.1% higher year on year, and consolidated net profit was 41.7% higher than the prior-year period.
Investors should distinguish between the two reporting bases. The standalone results track Vijaypd Ceutical’s own operations, while consolidated results incorporate subsidiaries or other group entities included in the accounts. Comparisons should be made on the same basis to avoid mixing the two sets of financial figures.
Got a follow-up? Ask IRIS
What happened to Vijaypd Ceutical’s IPO proceeds?
Vijaypd Ceutical confirmed that it had utilised 100% of its ₹19.25 crore IPO proceeds, with no reported deviation from the stated objects of the issue. The update is relevant because it provides clarity on the deployment of funds raised from public shareholders.
Of the total proceeds, ₹10.83 crore was deployed toward capital expenditure and ₹5.10 crore was used for debt repayment. The supplied disclosure does not specify the precise assets funded through capex, their commissioning status, or their expected revenue contribution.
Debt repayment can reduce borrowing requirements, but the H1 FY27 statement also showed higher finance charges than a year earlier. The filing does not explain the drivers of this increase, including the timing of debt reduction, working-capital borrowings or interest-rate effects. These matters remain relevant when assessing the company’s future cost structure.
What do the results mean for investors and operations?
The results show that Vijaypd Ceutical achieved substantial standalone revenue growth in H1 FY27, but profit remained below the prior-year level. For investors, this makes the relationship between sales growth, purchase costs, financing expenses and operating margins central to evaluating the earnings quality of the period.
The company’s historical standalone figures also show that profitability has varied. In H1 FY26, it reported sales of ₹51.33 crore, operating profit of ₹4.36 crore and an operating profit margin of 8.49%. The current period’s reported margin of about 4.4% suggests a lower level of profitability relative to revenue than in that earlier half year.
The absence of an earnings-call transcript limits visibility on management’s explanation of the margin movement and capex deployment. The company has disclosed the completed use of IPO funds, but it has not provided guidance on revenue, margins, order flow or additional capital expenditure in the supplied results material.
Conclusion
Vijaypd Ceutical’s H1 FY27 results reflect a 43.5% increase in standalone revenue to ₹73.67 crore, alongside a 1.9% decline in net profit to ₹2.37 crore. Higher purchase costs and finance charges constrained earnings, while the reported 4.4% operating margin indicates pressure on profitability despite stronger sales.
Investors will watch the next financial disclosure for evidence of whether higher revenue can translate into improved margins and profit. Important disclosed factors to monitor include finance charges, the operational effect of ₹10.83 crore of capex, and the impact of the company’s completed ₹5.10 crore debt repayment.


